Piramal Pharma has fully acquired Yapan Bio Private Limited for Rs 76 crore, increasing its stake to 74%. This move integrates Yapan's biologic manufacturing capabilities into Piramal Pharma's services, aiming for efficient development of complex therapies.
Piramal Pharma Completes Yapan Bio Acquisition
Piramal Pharma has completed the acquisition of an additional 40.67% equity stake in Yapan Bio Private Limited for approximately Rs 76 crore. This transaction increases Piramal Pharma's shareholding in Yapan Bio from 33.33% to 74.00%, changing Yapan Bio's status from an associate company to a subsidiary. ## What just happened Piramal Pharma Limited (PPL) finalized the purchase of 1,46,400 equity shares of Rs 10 each in Yapan Bio Private Limited. This move, following the exercise of a call option, gives PPL majority control over the company. ## Why this matters The acquisition allows Piramal Pharma to fully integrate Yapan Bio's expertise in advanced large molecule capabilities into its own service offerings. This integration is expected to enhance Piramal Pharma's ability to efficiently develop and scale complex biologic therapies. ## The backstory Yapan Bio Private Limited, incorporated in 2019, is a Contract Development and Manufacturing Organization (CDMO) specializing in process development, characterization, and GMP manufacturing services for vaccines and biologics. ## What changes now Yapan Bio will now operate as a subsidiary of Piramal Pharma, enabling closer alignment and strategic integration of its specialized services within Piramal Pharma's broader business. The promoter group of Piramal Pharma is now indirectly interested in Yapan Bio. ## Risks to watch While the filing focuses on the acquisition, potential risks could include the successful integration of Yapan Bio's operations and achieving the expected synergies in developing complex biologic therapies. Fluctuations in Yapan Bio's revenue, as seen in FY2026's dip, could also be a concern. ## Peer comparison As a CDMO focused on biologics, Yapan Bio operates in a growing but competitive market. Other Indian players in the CDMO space include Syngene International and Laurus Labs, which also offer specialized development and manufacturing services. Piramal Pharma's strategic acquisition aims to strengthen its position in this segment. ## Context metrics (time-bound) Yapan Bio reported revenues of Rs 26.91 crore in FY2024, Rs 54.40 crore in FY2025, and Rs 26.34 crore in FY2026. The total consideration for the additional 40.67% stake was approximately Rs 76 crore. ## What to track next Investors will be keen to observe how Piramal Pharma leverages Yapan Bio's capabilities to develop new biologic therapies and how this integration impacts the company's overall financial performance and market position in the CDMO sector.
